CA2859627A1 - Anti-human ctgf antibody - Google Patents
Anti-human ctgf antibody Download PDFInfo
- Publication number
- CA2859627A1 CA2859627A1 CA2859627A CA2859627A CA2859627A1 CA 2859627 A1 CA2859627 A1 CA 2859627A1 CA 2859627 A CA2859627 A CA 2859627A CA 2859627 A CA2859627 A CA 2859627A CA 2859627 A1 CA2859627 A1 CA 2859627A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- human
- variable region
- chain variable
- ctgf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011-281811 | 2011-12-22 | ||
| JP2011281811 | 2011-12-22 | ||
| PCT/JP2012/083206 WO2013094723A1 (ja) | 2011-12-22 | 2012-12-21 | 新規抗ヒトｃｔｇｆ抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2859627A1 true CA2859627A1 (en) | 2013-06-27 |
Family
ID=48668601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2859627A Abandoned CA2859627A1 (en) | 2011-12-22 | 2012-12-21 | Anti-human ctgf antibody |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9587015B2 (enExample) |
| EP (1) | EP2796550B1 (enExample) |
| JP (1) | JP6040943B2 (enExample) |
| KR (1) | KR20140107507A (enExample) |
| CN (1) | CN104011206B (enExample) |
| AR (1) | AR089425A1 (enExample) |
| BR (1) | BR112014015405A2 (enExample) |
| CA (1) | CA2859627A1 (enExample) |
| EA (1) | EA029290B1 (enExample) |
| ES (1) | ES2665851T3 (enExample) |
| IN (1) | IN2014CN04615A (enExample) |
| MX (1) | MX345019B (enExample) |
| PL (1) | PL2796550T3 (enExample) |
| PT (1) | PT2796550T (enExample) |
| TW (1) | TW201333034A (enExample) |
| WO (1) | WO2013094723A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109824777A (zh) * | 2019-03-15 | 2019-05-31 | 辽宁何氏医学院 | 一种具有抑制玻璃体视网膜纤维化病变作用的单克隆抗体及其制备方法和应用 |
| US20200369759A1 (en) | 2019-05-23 | 2020-11-26 | Fibrogen, Inc. | Methods of treatment of muscular dystrophies |
| MY208454A (en) * | 2019-06-04 | 2025-05-09 | Shanghai hengrui pharmaceutical co ltd | Anti-connective tissue growth factor antibody and application thereof |
| AU2021390125A1 (en) * | 2020-12-03 | 2023-06-22 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising anti-connective tissue growth factor antibody |
| US20250163158A1 (en) | 2022-06-07 | 2025-05-22 | Astellas Pharma Inc. | Pharmaceutical composition containing anti-integrin alpha11 antibody for treatment or prevention of aging-related diseases |
| WO2024095964A1 (ja) | 2022-10-31 | 2024-05-10 | アステラス製薬株式会社 | Ｔｏｌｌ様受容体７／８デュアルアゴニスト化合物を含む抗体薬物複合体 |
| TW202502816A (zh) * | 2023-03-10 | 2025-01-16 | 大陸商上海濟煜醫藥科技有限公司 | 一種靶向ｃｔｇｆ的抗體或其抗原結合片段及其應用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE8808645U1 (de) | 1988-07-06 | 1988-08-25 | Hofer, Daniel, 7730 Villingen-Schwenningen | Anzeigeeinrichtung für Feuerlöscher |
| KR100337069B1 (ko) | 1993-03-11 | 2002-10-11 | 사이단호진가가쿠오요비겟세이리요호오겐큐쇼 | 항-hiv모노클로날항체 |
| WO1999033878A1 (en) * | 1997-12-25 | 1999-07-08 | Japan Tobacco Inc. | Monoclonal antibody against connective tissue growth factor and medicinal uses thereof |
| JP4537507B2 (ja) | 1997-12-25 | 2010-09-01 | アムジェン インコーポレイテッド | 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途 |
| US6492129B1 (en) * | 1998-12-14 | 2002-12-10 | University Of Miami | Fragments of connective tissue growth factor that induce extracellular matrix synthesis, collagen synthesis and/or myofibroblast differentiation |
| US7115390B1 (en) | 1998-12-14 | 2006-10-03 | Fibrogen, Inc. | Connective tissue growth factor fragments and methods and uses thereof |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7405274B2 (en) | 2003-06-04 | 2008-07-29 | Fibrogen, Inc. | Connective tissue growth factor antibodies |
| JP2009067678A (ja) * | 2005-12-07 | 2009-04-02 | Nihon Nosan Kogyo Kk | 結合組織増殖因子に対する抗体又はそれを含む組成物 |
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
-
2012
- 2012-12-21 EP EP12860742.1A patent/EP2796550B1/en active Active
- 2012-12-21 CA CA2859627A patent/CA2859627A1/en not_active Abandoned
- 2012-12-21 KR KR1020147020039A patent/KR20140107507A/ko not_active Abandoned
- 2012-12-21 PL PL12860742T patent/PL2796550T3/pl unknown
- 2012-12-21 IN IN4615CHN2014 patent/IN2014CN04615A/en unknown
- 2012-12-21 US US14/367,081 patent/US9587015B2/en not_active Expired - Fee Related
- 2012-12-21 MX MX2014007681A patent/MX345019B/es active IP Right Grant
- 2012-12-21 BR BR112014015405A patent/BR112014015405A2/pt unknown
- 2012-12-21 AR ARP120104933A patent/AR089425A1/es unknown
- 2012-12-21 PT PT128607421T patent/PT2796550T/pt unknown
- 2012-12-21 EA EA201491240A patent/EA029290B1/ru not_active IP Right Cessation
- 2012-12-21 JP JP2013550349A patent/JP6040943B2/ja not_active Expired - Fee Related
- 2012-12-21 TW TW101148989A patent/TW201333034A/zh unknown
- 2012-12-21 ES ES12860742.1T patent/ES2665851T3/es active Active
- 2012-12-21 CN CN201280063995.5A patent/CN104011206B/zh not_active Expired - Fee Related
- 2012-12-21 WO PCT/JP2012/083206 patent/WO2013094723A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ES2665851T3 (es) | 2018-04-27 |
| MX345019B (es) | 2017-01-11 |
| EP2796550A4 (en) | 2015-08-19 |
| EA201491240A1 (ru) | 2014-11-28 |
| EP2796550B1 (en) | 2018-02-28 |
| PT2796550T (pt) | 2018-04-18 |
| US20140343258A1 (en) | 2014-11-20 |
| CN104011206A (zh) | 2014-08-27 |
| WO2013094723A1 (ja) | 2013-06-27 |
| EP2796550A1 (en) | 2014-10-29 |
| US9587015B2 (en) | 2017-03-07 |
| CN104011206B (zh) | 2017-03-08 |
| TW201333034A (zh) | 2013-08-16 |
| KR20140107507A (ko) | 2014-09-04 |
| EA029290B1 (ru) | 2018-03-30 |
| IN2014CN04615A (enExample) | 2015-09-18 |
| JP6040943B2 (ja) | 2016-12-07 |
| AR089425A1 (es) | 2014-08-20 |
| JPWO2013094723A1 (ja) | 2015-04-27 |
| PL2796550T3 (pl) | 2018-08-31 |
| BR112014015405A2 (pt) | 2017-06-13 |
| MX2014007681A (es) | 2014-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9587015B2 (en) | Anti-human CTGF antibody | |
| DK2743348T3 (en) | Hitherto UNKNOWN ANTI-HUMAN NGF ANTIBODY | |
| JP6699551B2 (ja) | 新規抗ヒトＴｉｅ２抗体 | |
| KR101589135B1 (ko) | 인간화 항-ｅｍａｐｉｉ 항체 및 이의 용도 | |
| CN102481340A (zh) | 干细胞靶向 | |
| TWI843763B (zh) | 抗人類Fn14抗體 | |
| EP3109320B1 (en) | New anti-human pai-1 antibody | |
| CN111196849A (zh) | 抗硬骨素抗体、其抗原结合片段及其医药用途 | |
| EP2821416B1 (en) | Novel anti-human il-23 receptor antibody | |
| WO2022136685A1 (en) | Antibody compositions for treatment of corona virus infection | |
| US11976115B2 (en) | Antibody binding to human IL-1β, preparation method therefor and use thereof | |
| US20220325000A1 (en) | Monoclonal antibody which targets tfpi | |
| EP4578877A1 (en) | Antibody fusion protein targeting fap and tgf-beta, and use thereof | |
| US20250163145A1 (en) | NOVEL Nav1.7 MONOCLONAL ANTIBODY | |
| JP7690612B2 (ja) | 抗ｍａｓｐ－２抗体及びその使用 | |
| US20250282862A1 (en) | Zip12 antibody | |
| RU2787044C2 (ru) | АНТИТЕЛО ПРОТИВ Fn14 ЧЕЛОВЕКА | |
| JPWO2019054460A1 (ja) | 抗ｒａｍｐ２抗体 | |
| WO2025256571A1 (zh) | 靶向b7h7和cd3的双特异性抗体及其应用 | |
| AU2019284320A1 (en) | APJ antibody, fusion protein thereof with Elabela, and pharmaceutical compositions and use thereof | |
| HK1234078A1 (en) | Novel anti-human tie2 antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20171122 |
|
| FZDE | Dead |
Effective date: 20210106 |